FollowMyHealth Patient Portal

Faculty Physicians

John M. Lasala, MD, PhD, FACC

Associate Professor, Medicine
Director, Interventional Cardiology
Medical Director, Cardiac Catheterization Lab

Specialty Areas

Cardiology
Cardiac Catheterization
Interventional Cardiology

Board Certifications

Cardiology
Internal Medicine

Referral Information

Physician Referral Required

Areas of Clinical Interest

Interventional cardiology, cardiac catheterizations, coronary artery disease, circulation, angioplasty, percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction, coronary-artery stenting, Wolff-Parkinson White syndrome, ascending and descending aortic dissections, aortic aneurysms

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Barnes-Jewish Hospital

1 Barnes-Jewish Hospital Plaza
St. Louis, MO 63110

Office Phone: 314-362-2284

Education

Education

Fellowship: Intervential Cardiology, Yale University School of Medicine, New Haven, Connecticut 1990
Fellowship: Postdoctoral Cardiology, Yale University School of Medicine, New Haven, Connecticut 1989
Residency: Internal Medicine, Barnes Hospital, Washington University School of Medicine, St. Louis, Missouri 1986
Fellowship: Postdoctoral Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri 1979
Medical Degree: University Of Connecticut, Storrs, Connecticut 1983
Ph.D.: St. Louis University, St. Louis, Missouri 1979
B.A.: Drew University, Madison, New Jersey 1975

Publication & Research

Publication & Research

Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement.
Lindman BR, Goldstein JS, Nassif ME, Zajarias A, Novak E, Tibrewala A, Vatterott AM, Lawler C, Damiano RJ, Moon MR, Lawton JS, Lasala JM, Maniar HS
Heart. 2015 Apr; 101(7)537-45. doi: 10.1136/heartjnl-2014-307057.

PMID:
    25605654
    [PubMed - indexed for MEDLINE]
Related citations


Outcomes of coronary stenoses deferred revascularization for borderline versus nonborderline fractional flow reserve values.
Depta JP, Patel JS, Novak E, Masrani SK, Raymer D, Facey G, Patel Y, Zajarias A, Lasala JM, Singh J, Bach RG, Kurz HI
Am J Cardiol. 2014 Jun 1; 113(11)1788-93. doi: 10.1016/j.amjcard.2014.03.004.

PMID:
    24837255
    [PubMed - indexed for MEDLINE]
Related citations


Atrial septal defect closure.
Vasquez AF, Lasala JM
Cardiol Clin. 2013 Aug; 31(3)385-400. doi: 10.1016/j.ccl.2013.05.003.

PMID:
    23931101
    [PubMed - indexed for MEDLINE]
Related citations


Long-term clinical outcomes with the use of a modified provisional jailed-balloon stenting technique for the treatment of nonleft main coronary bifurcation lesions.
Depta JP, Patel Y, Patel JS, Novak E, Yeung M, Zajarias A, Kurz HI, Lasala JM, Bach RG, Singh J
Catheter Cardiovasc Interv. 2013 Nov 1; 82(5)E637-46. doi: 10.1002/ccd.24778.

PMID:
    23420654
    [PubMed - indexed for MEDLINE]
Related citations


A modified provisional stenting approach to coronary bifurcation lesions: clinical application of the "jailed-balloon technique".
Singh J, Patel Y, Depta JP, Mathews SJ, Cyrus T, Zajarias A, Kurz HI, Lasala JM, Bach RG
J Interv Cardiol. 2012 Jun; 25(3)289-96. doi: 10.1111/j.1540-8183.2011.00716.x.

PMID:
    22364484
    [PubMed - indexed for MEDLINE]
Related citations


Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses.
D'Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, ten Berg JM, Brodie BR, Urban P, Jensen LO, Sardi G, Waksman R, Lasala JM, Schulz S, Stone GW, Airoldi F, Colombo A, Lemesle G, Applegate RJ, Buonamici P, Kirtane AJ, Undas A, Sheiban I, Gaita F, Sangiorgi G, Modena MG, Frati G, Biondi-Zoccai G
Int J Cardiol. 2013 Jul 31; 167(2)575-84. doi: 10.1016/j.ijcard.2012.01.080.

PMID:
    22360945
    [PubMed - indexed for MEDLINE]
Related citations


Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).
Reynolds MR, Magnuson EA, Wang K, Lei Y, Vilain K, Walczak J, Kodali SK, Lasala JM, O'Neill WW, Davidson CJ, Smith CR, Leon MB, Cohen DJ, PARTNER Investigators
Circulation. 2012 Mar 6; 125(9)1102-9. doi: 10.1161/CIRCULATIONAHA.111.054072.

PMID:
    22308299
    [PubMed - indexed for MEDLINE]
Related citations


Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions.
Patel Y, Depta JP, Novak E, Yeung M, Lavine K, Banerjee S, Lin CH, Zajarias A, Kurz HI, Lasala JM, Bach RG, Singh J
Am J Cardiol. 2012 Apr 1; 109(7)960-5. doi: 10.1016/j.amjcard.2011.11.022.

PMID:
    22296739
    [PubMed - indexed for MEDLINE]
Related citations


Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme.
Lee MS, Yang T, Lasala JM, Cox DA, Bowman TS, Starzyk RM, Dawkins KD
EuroIntervention. 2011 Jul; 7(3)314-22. doi: 10.4244/EIJV7I3A55.

PMID:
    21729833
    [PubMed - indexed for MEDLINE]
Related citations


Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries.
Brilakis ES, Lasala JM, Cox DA, Bowman TS, Starzyk RM, Dawkins KD
J Interv Cardiol. 2011 Aug; 24(4)342-50. doi: 10.1111/j.1540-8183.2011.00646.x.

PMID:
    21492221
    [PubMed - indexed for MEDLINE]
Related citations


Defect closure in the lipomatous hypertrophied atrial septum with the Amplatzer muscular ventricular septal defect closure device: a case series.
Lin CH, Balzer DT, Lasala JM
Catheter Cardiovasc Interv. 2011 Jul 1; 78(1)102-7. doi: 10.1002/ccd.22858.

PMID:
    21416575
    [PubMed - indexed for MEDLINE]
Related citations


A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients.
Baran KW, Lasala JM, Cox DA, Mascioli SR, Song A, Deshpande MC, Jacoski MV, Dawkins KD, ARRIVE Investigators
EuroIntervention. 2011 Mar; 6(8)949-54. doi: 10.4244/EIJV6I8A165.

PMID:
    21330242
    [PubMed - indexed for MEDLINE]
Related citations


Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program.
Huang PH, Yeung M, Lasala JM, Cox DA, Bowman TS, Starzyk RM, Dawkins KD
J Interv Cardiol. 2011 Jun; 24(3)232-40. doi: 10.1111/j.1540-8183.2010.00622.x.

PMID:
    21299633
    [PubMed - indexed for MEDLINE]
Related citations


Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.
Mikhail GW, Gerber RT, Cox DA, Ellis SG, Lasala JM, Ormiston JA, Stone GW, Turco MA, Joshi AA, Baim DS, Colombo A
JACC Cardiovasc Interv. 2010 Dec; 3(12)1250-9. doi: 10.1016/j.jcin.2010.08.020.

PMID:
    21232718
    [PubMed - indexed for MEDLINE]
Related citations


Bleeding avoidance strategies and percutaneous coronary intervention.
Huang PH, Zajarias A, Lasala JM
JAMA. 2010 Sep 8; 304(10)1068; author reply 1068-9. doi: 10.1001/jama.2010.1255.

PMID:
    20823430
    [PubMed - indexed for MEDLINE]
Related citations


Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk RM, Dawkins KD
JACC Cardiovasc Interv. 2010 Jul; 3(7)742-50. doi: 10.1016/j.jcin.2010.04.012.

PMID:
    20650436
    [PubMed - indexed for MEDLINE]
Related citations


The SCAI Structural Heart Disease Council: toward addressing training, credentialing, and guidelines for structural heart disease intervention.
Feldman T, Ruiz CE, Hijazi ZM, SCAI Structural Heart Disease Council
Catheter Cardiovasc Interv. 2010 Oct 1; 76(4)E87-9. doi: 10.1002/ccd.22701.

PMID:
    20602476
    [PubMed - indexed for MEDLINE]
Related citations


Anatomic distortion of the right coronary artery as a complication of lung transplantation.
Melby SJ, Larue SJ, Lasala JM, Pal N, Lakshminarasimhachar A, Trulock EP, Kreisel D, Pasque MK, Puri V, Patterson GA, Krupnick AS
Ann Thorac Surg. 2010 Jun; 89(6)2000-1. doi: 10.1016/j.athoracsur.2009.10.070.

PMID:
    20494065
    [PubMed - indexed for MEDLINE]
Related citations


Use of mechanical assist during high-risk PCI and STEMI with cardiogenic shock.
Cyrus T, Mathews SJ, Lasala JM
Catheter Cardiovasc Interv. 2010 Mar 1; 75 Suppl 1S1-6. doi: 10.1002/ccd.22366.

PMID:
    20333708
    [PubMed - indexed for MEDLINE]
Related citations


Evidence based management of patients undergoing PCI. Conclusion.
Lasala JM, Mehran R, Moses JW, Popma JJ, Reiner JS, Sharma SK, Vetrovec GW
Catheter Cardiovasc Interv. 2010 Mar 1; 75 Suppl 1S43-5. doi: 10.1002/ccd.22411.

PMID:
    20333707
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2014.

Company Name: Abiomed

Royalties:

Equity: Yes

Consulting/Advisory Board:

Speaker Fees: $50,001 - $100,000

Reporting Date: May 01, 2015


Company Name: AGA/St. Jude

Royalties:

Equity: No

Consulting/Advisory Board:

Speaker Fees: $10,001 - $25,000

Reporting Date: May 01, 2015


Company Name: Direct Flow Medical

Royalties:

Equity: Yes

Consulting/Advisory Board:

Speaker Fees:

Reporting Date: May 01, 2015